Table 1.

Currently available PCR or NGS-based clinical ctDNA assays

Method	Assay	Cancer	Gene	Company
PCR-based	Cobas EGFR Mutations Test v2	NSCLC	EGFR del19, EGFR L858R and EGFR T790M	Roche Molecular Diagnostics
	Therascreen EGFR RGQ Plasma PCR kit	NSCLC	EGFR del19 and EGFR L858R	Qiagen Inc
	AmoyDx Super-ARMS EGFR mutation test	NSCLC	EGFR del19, EGFR L858R and EGFR T790M	AmoyDx
	OncoBEAM RAS CRC Kit	CRC	KRAS and NRAS mutations	Sysmex Inostics
	Idylla ctKRAS Mutation Test and Idylla ctNRAS-BRAF Mutation Test	CRC	KRAS, NRAS and BRAF mutations	Biocartis, Inc.
NGS-based	Guardant360	Solid tumours	74 genes and MSI	Guardant Health
	FoundationOne Liquid	Solid tumours	70 genes and MSI	Foundation Medicine Inc.
	PlasmaSELECT	Solid tumours	64 genes and MSI	Personal Genome Diagnostics
	Oncomine Lung cfDNA Assay	NSCLC	11 genes	ThermoFisher Scientific
	Reveal ctDNA 28 Kit	Solid tumours	28 genes	ArcherDX
	OptiSeq NGS Pan-Cancer Panel	Solid tumours	65 genes	DiaCarta

CRC, colorectal cancer; ctDNA, circulating tumour DNA; MSI, microsatellite instability; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction.